{"name":"Viatris Inc.","slug":"viatris","ticker":"VTRS","exchange":"NASDAQ","domain":"viatris.com","description":"Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distr","hq":"Canonsburg, PA","founded":0,"employees":"30000","ceo":"Scott Smith","sector":"Generics & Biosimilars","stockPrice":13.55,"stockChange":0.39,"stockChangePercent":2.96,"marketCap":"$15.8B","metrics":{"revenue":14299900000,"revenueGrowth":5,"grossMargin":39.5,"rdSpend":751100000,"netIncome":-3514899968,"cash":1512999936,"dividendYield":3.65,"peRatio":5.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"1953-01-01","label":"Phenytoin Sodium first approved","drug":"Phenytoin Sodium","drugSlug":"phenytoin","type":"approval","sentiment":"positive"},{"date":"1990-01-01","label":"Cardura first approved","drug":"Cardura","drugSlug":"doxazosin","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-06-01","label":"Atorvastatin patent cliff ($1.4B at risk)","drug":"Atorvastatin","type":"patent_expiry","sentiment":"negative"},{"date":"2028-06-01","label":"Lisinopril patent cliff ($1.1B at risk)","drug":"Lisinopril","type":"patent_expiry","sentiment":"negative"},{"date":"2030-06-01","label":"Metformin patent cliff ($2.5B at risk)","drug":"Metformin","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"cardiovascular","drugs":[{"name":"AC-076 for s.c. administration","genericName":"AC-076 for s.c. administration","slug":"ac-076-for-s-c-administration","indication":"Other","status":"phase_1"},{"name":"ACT-246475","genericName":"ACT-246475","slug":"act-246475","indication":"Other","status":"phase_1"},{"name":"Dovprela","genericName":"Dovprela","slug":"dovprela","indication":"Other","status":"phase_2"},{"name":"diazepam 20 mg","genericName":"diazepam 20 mg","slug":"diazepam-20-mg","indication":"Other","status":"marketed"},{"name":"gabapentin 600 mg","genericName":"gabapentin 600 mg","slug":"gabapentin-600-mg","indication":"Other","status":"marketed"},{"name":"pregabalin 450 mg","genericName":"pregabalin 450 mg","slug":"pregabalin-450-mg","indication":"Other","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Cardura","genericName":"DOXAZOSIN","slug":"doxazosin","indication":"Benign prostatic hyperplasia","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Phenytoin Sodium","genericName":"PHENYTOIN","slug":"phenytoin","indication":"Bipolar disorder in remission","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"MR-107A-02","genericName":"MR-107A-02","slug":"mr-107a-02","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Cardura","genericName":"DOXAZOSIN","slug":"doxazosin","phase":"marketed","mechanism":"Alpha-1B adrenergic receptor","indications":["Benign prostatic hyperplasia","Hypertensive disorder"],"catalyst":""},{"name":"Phenytoin Sodium","genericName":"PHENYTOIN","slug":"phenytoin","phase":"marketed","mechanism":"Phenytoin Sodium works by stabilizing the threshold against hyperexcitability caused by excessive stimulation.","indications":["Bipolar disorder in remission","Epilepsy","Epilepsy characterized by intractable complex partial seizures","Lennox-Gastaut syndrome","Localization-related epilepsy"],"catalyst":""},{"name":"AC-076 for s.c. administration","genericName":"AC-076 for s.c. administration","slug":"ac-076-for-s-c-administration","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACT-246475","genericName":"ACT-246475","slug":"act-246475","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Dovprela","genericName":"Dovprela","slug":"dovprela","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MR-107A-02","genericName":"MR-107A-02","slug":"mr-107a-02","phase":"phase_3","mechanism":"MR-107A-02 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"diazepam 20 mg","genericName":"diazepam 20 mg","slug":"diazepam-20-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"gabapentin 600 mg","genericName":"gabapentin 600 mg","slug":"gabapentin-600-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"pregabalin 450 mg","genericName":"pregabalin 450 mg","slug":"pregabalin-450-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Viatris Reports Fourth-Quarter and Full-Year 2023 Financial Results","summary":"Viatris reported fourth-quarter and full-year 2023 financial results, with net sales of $4.4 billion and adjusted diluted earnings per share of $1.35.","drugName":"","sentiment":"neutral"},{"date":"2023-11-01","type":"deal","headline":"Viatris and Biocon Biologics Announce Partnership to Develop and Commercialize Biosimilars","summary":"Viatris and Biocon Biologics announced a partnership to develop and commercialize biosimilars, expanding Viatris' presence in the biosimilars market.","drugName":"","sentiment":"positive"},{"date":"2023-09-01","type":"regulatory","headline":"FDA Approves Viatris' Generic Version of Eliquis","summary":"The FDA approved Viatris' generic version of Eliquis, a blood thinner used to prevent stroke and blood clots.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOQ0FjNHB1VWh0TWhqVWtNa3ZjYWttZlNBNkM1bGRiUHNOZjZvVktrRjY2a194Qkh3WHdSbDBDeEJoUDNKSXdWLThhWjgzZEhjczctQUhiOE1heTdvb0g1WkpwLUNVSW1fSW56NXpPaWFUWDNjS3RQTE1tX1lwZEZYVjI5SHhZaHNGS3BRRldBYzAtdjMzWHBOWktqalFhMTdoMU0tcFVJeVEwd0pL?oc=5","date":"2026-03-02","type":"earnings","source":"Finviz","summary":"Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4 - Finviz","headline":"Spotting Winners: Viatris (NASDAQ:VTRS) And Generic Pharmaceuticals Stocks In Q4","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOSmtmT1Q4eW82WWVMbUVqVTl0Wkdfa09BaEpqaHNob0JTZHAwWTZGTy0xdlJOTVF1bnFIdE1CaDdTTFBCV2JHa1VPQ0hHVU5JYTJNblF5T1hGWk9qVUxxdXZGTFZHMHdUcklqX3BNNVd4ZlBiUldUSDV5dndoRVhjNjhwVmEzUVVkRWRuV1FCMTd4VFBhOWxGbDV3WEtSVHNpc01mMGN6NVNwTTloYm9zaQ?oc=5","date":"2026-02-23","type":"earnings","source":"TradingView","summary":"Viatris Stock to Report Q4 Earnings: What's in the Cards? - TradingView","headline":"Viatris Stock to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQ1hpbEZhUEM4UXFzdGVtZG5vRG0xNlR6MG1xRldKemZSdEI1d2pYMXlJRElaUTh1VXZPRy1Bb1B2MEtLNU9IRUxvV1JOSklEdkpwZzBHeVV5ZTlfajU1aU9ZMjNNNmViMzJvRUp6clFBWUZpYzRNY1RGelJaWTNfcFQ4SE8xVGcxT2FvdlRSRENkaURObDF6M3loZWZqMmozTzZiOXowbDFtTEJ1WEtPVEM0cWNYWDlMaEZNc0lnYw?oc=5","date":"2026-02-23","type":"earnings","source":"TradingView","summary":"What's in Store for These 5 Medical Companies This Earnings Season? - TradingView","headline":"What's in Store for These 5 Medical Companies This Earnings Season?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQUHZGaHdhMWNZa2thRXFQdlEySVJjTEtkM3MzakxxZFVrNGYySE9aMGpONElnaDhSOHpvUlNZNl84RkdpT0FBb0hLaG1JUmpORXJZWWx2ekl6VkZLMF9kZVhXN0dDRkpuZTdRcVl0UmVrLXJ2ZXIybElGTjh1dzBQMEZpZ2RLT0pOQk41UFBvMkx5NUdCRmNqenI5WVNyNjczeXdmMjY1ZmRrS25uUElSd01fclE0eEdhS3ROZ1NxUzZidw?oc=5","date":"2026-02-20","type":"pipeline","source":"Seeking Alpha","summary":"Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation - Seeking Alpha","headline":"Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQQ2hYWkZYVWRhUUV6S1Z0S0dtbHBCSDU4VG5Zbnc4bm51WDl6clFFZnVmYzdTYzVSazhuNlE1Ui1EY01ScEZDaUJNempTZFk1YnNSMEtJTWJXSWhuWjg2Q3NOMWhTRFVReDJkOE9VU0lFOFV5Sk10ZTM2VFpKQWlGVmdpcmZuTEhSSVU1UW1sLThXRWE4QWlSWkVKU3NmdkFEY1RqQ2Q3WXVwbVlqdzViX3BPSFVwdw?oc=5","date":"2026-02-18","type":"earnings","source":"Finviz","summary":"UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - Finviz","headline":"UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxNTTdOeW1TZEhTU3E3RHE1UWpwUUVpdUVMSU1YRG5DYkF3SkN0Zm9RR2R5MG5xOEV1Tm1tMW1pVV9rZU1hd0xpbkg1Z3ZQeTlNMU1DRE5RalFzY0U0RXZ2LXMySWluYU9SRXhrSE01dkVVVjdRU0V6NUtxMDc2MTFxZA?oc=5","date":"2026-02-10","type":"pipeline","source":"Yahoo Finance","summary":"Where is Viatris Inc. (VTRS) Headed According to the Street? - Yahoo Finance","headline":"Where is Viatris Inc. (VTRS) Headed According to the Street?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQaUVmZzZKZUc4OVJnMzBreUlmYVBucXRaOHZKdHhneWxhQ2RWSzBxcVRaZkdwUDF6b2NXMHh0NlFacGRJN1htVFI0YVluVlBDX0N4dHRfbVlxd1dMSzNzNUVfUU9GS0tFWkg2ZUFROHZHWVpXbW9KWDRsSWR1MDRXaWNPLXB2c3FkdGpEd193OUFVY0tMRjEzZjdoeTlocWVWa1NfYnVGTUtGN0JDS0xOMFluR0VoRi1HMWVpZTYwcXhIN3hyUzRtXzY4aU8za3FkWFZNaC1xVVBsNmNCRWpF?oc=5","date":"2026-01-14","type":"pipeline","source":"FinancialContent","summary":"Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent","headline":"Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQbFhpYVg5UWdBbGFPMHhoQWpjSG54dXhYY3VVZzRMUEVOa01DZkd5ekZYeFpoVFp5QjEzcW1vQkFGbU9HUlpMaUVMclJtZFlVQTgxSTRyT3dFekNlelo1akkyTEc3MmotdTlFS3U2b1VFQXpMWGQ0Z2w2Q0pzRlpoR1AtTnJaQWZldEhNdFdQX1QtUQ?oc=5","date":"2025-12-30","type":"pipeline","source":"Yahoo Finance","summary":"Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves - Yahoo Finance","headline":"Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNQnZQR3NNUTBmSWs4QllVaTBiYS1POGM4RWpHc2tZV3VLUFNiWG1hT2VncE85cy12MmpMcWQ1cG84bjBJN3Vicjg3aHVZQy1XcHloQ3ZoUUNVUmlPbUlsU2pVZURXZ1VMcTVGZlk0TkJiNm9fWV9WUzhnVGpNMklrbFc5TzZsZlgzNXlZNmhkaW5WVWxvQmw2bDBka0tUUjRTTVBCUHVmenhhQ3BjSFB5c0E2WlJLcGJKUnc?oc=5","date":"2025-11-06","type":"earnings","source":"Viatris","summary":"Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance - Viatris","headline":"Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPd2ZMa1BZSHQtWTRGdnEyT1ZCODhic3JCa0xiVXhDRHlfaEt4YlFNLUFrOGc3VjEtMF85bzQ2U29FZnFXUExQRUZsaE94cGpETFk3dnlua0YtcXoxcDVCcGhpM1pkUEE2dy10M09aNmFTbm1vTGxreXMyYVVtd3M1MDdKeWc?oc=5","date":"2025-10-21","type":"deal","source":"Yahoo Finance","summary":"Viatris Inc. (VTRS) Acquires Aculys Pharma, Inc - Yahoo Finance","headline":"Viatris Inc. (VTRS) Acquires Aculys Pharma, Inc","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPbUNFWVRpV0UzcXI1bTc4NDRodmViQU40MVpBc290dHl2NTIwODdhX3VTZDJoUEJZdGVZYUdQRDU2UU9RQXRCWjdxQV9pY3lWRVZJV1RlU2hHTEJib2g3QzJVS21mNlZodnlNamNqWXhqLXY5NVZ2eXBKaEJ4aklabUJyTXhPZURUZzk5TnJ2elZXb1hyT3FuamhjSGYzTHpIdHRyWA?oc=5","date":"2025-10-17","type":"pipeline","source":"Seeking Alpha","summary":"Teva Vs. Viatris: Who Will Dominate In President Trump's America? (NASDAQ:VTRS) - Seeking Alpha","headline":"Teva Vs. Viatris: Who Will Dominate In President Trump's America? (NASDAQ:VTRS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAJBVV95cUxQa2xwOWxPQkVIQXRkbDB2RFJ1d2RwSm9TUmt3UTlMa0t0NEVJcXlGTFNyYWdKQVdFYktnZVkxRDhHVmNVbm9aU0w5RG5fQk9vdFF4OE4wNHBmZGtwc0tUeTJQT1l2aUMtd0l5czczTjRJaGtmby1rd1hjTFctLTFWTjZnNDNYdC1LdE9aRkJqRGd3NWxSeFJNdDlsd3pxaVFQZzJzNkhTQ2xnb3hNdy1ONGdwWEVjRVZ2Y1VKQVJkZ3UzeWR0eWltSEFoeV9wUGVFRmxodm9MT25sUF9hT3F1Wi1VVDhkLWtKbHJ4TWZmSUtvSFhZdnI2OFlTWW1vdFlYSDV2cXREYVJ2c1UteW9GUUQ1SW1hdDRmZTlQVXZxUl9kZ3hpSU82eGNkWW01ZU1SZ2JKT1gtQ1V4Tm8tLXBkQXFiN19FSEU2VHlnNQ?oc=5","date":"2025-10-15","type":"pipeline","source":"PR Newswire","summary":"Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan and Certain Other Markets in the Asia-Pacific Region - PR Newswire","headline":"Viatris Completes Acquisition of Aculys Pharma Including Exclusive Rights to Pitolisant in Japan and to Spydia® in Japan","sentiment":"neutral"}],"patents":[{"drugName":"Atorvastatin","drugSlug":"atorvastatin","patentNumber":"","type":"Patent Cliff","expiryDate":"2027-06-01","territory":"US","annualRevenue":1400000000},{"drugName":"Lisinopril","drugSlug":"lisinopril","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1100000000},{"drugName":"Metformin","drugSlug":"metformin","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":2500000000}],"drugCount":9,"phaseCounts":{"marketed":5,"phase_1":2,"phase_2":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Mylan N.V.","Sandoz International GmbH","Teva Pharmaceutical Industries Ltd."],"therapeuticFocus":["Cardiovascular","Oncology","Infectious Diseases"],"financials":{"source":"sec_edgar","revenue":14299900000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":14299900000,"period":"2025-12-31"},{"value":14739300000,"period":"2024-12-31"},{"value":14739300000,"period":"2024-12-31"},{"value":15426900000,"period":"2023-12-31"},{"value":15426900000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":751100000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":0,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":37193100000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":13.55,"previousClose":13.16,"fiftyTwoWeekHigh":16.47,"fiftyTwoWeekLow":6.85,"fiftyTwoWeekRange":"6.85 - 16.47","fiftyDayAverage":14.31,"twoHundredDayAverage":11.4,"beta":0.82,"enterpriseValue":28337330176,"forwardPE":5.1,"priceToBook":1.06,"priceToSales":1.1,"enterpriseToRevenue":1.98,"enterpriseToEbitda":7.16,"pegRatio":0,"ebitda":3958200064,"ebitdaMargin":27.7,"freeCashflow":2431462400,"operatingCashflow":2315899904,"totalDebt":14698000384,"debtToEquity":99.9,"currentRatio":1.38,"returnOnAssets":2,"returnOnEquity":-21.1,"analystRating":"2.1 - Buy","recommendationKey":"buy","numberOfAnalysts":9,"targetMeanPrice":15.72,"targetHighPrice":20,"targetLowPrice":12,"dividendRate":0.48,"payoutRatio":9.6,"fiveYearAvgDividendYield":0.89,"exDividendDate":1773014400,"insiderHeldPercent":0.4,"institutionHeldPercent":86.3,"sharesOutstanding":1164420909,"floatShares":1141364290,"sharesShort":28323140,"shortRatio":2.56,"shortPercentOfFloat":2.5,"epsTrailing":-3,"epsForward":2.67,"revenuePerShare":12.21,"bookValue":12.78,"officers":[{"age":63,"name":"Mr. Scott Andrew Smith Ph.D.","title":"CEO & Director"},{"age":42,"name":"Ms. Theodora  Mistras","title":"Chief Financial Officer"},{"age":57,"name":"Mr. Paul B. Campbell","title":"Chief Accounting Officer & Corporate Controller"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.viatris.com","phone":"724 514 1800"}}